A US company that is investigating therapeutics based on RNA interference (RNAi) has reached agreement with investors to raise $8.3 million in a public offering on Nasdaq. The company, RXi Pharmaceuticals Corp, went public in March 2008. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals
